Moderna and Merck's Personalized mRNA Vaccine Cuts Melanoma Recurrence

The roots of this breakthrough trace back to the rapid development of mRNA technology during the Covid-19 pandemic. Moderna, known for its coronavirus vaccine, partnered with pharmaceutical giant Merck to explore whether mRNA could help the immune system fight cancer, not just viruses.

The focus was on melanoma, a particularly dangerous form of skin cancer that often returns even after surgery. Researchers believed that a personalized vaccine, tailored to the genetic makeup of each patient's tumor, could train the immune system to recognize and attack cancer cells more effectively.

Early studies suggested this approach might work, but it was not until a large phase 3 clinical trial that its full potential was tested.

On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, called Intismeran, showed promising results in a late-stage trial. According to Global News and Axios, the companies reported that the vaccine prevented the recurrence and spread of melanoma when given to high-risk patients after surgery.

The vaccine was tested alongside Merck's immunotherapy drug Keytruda, which is already widely used for melanoma. The combination appeared to significantly reduce the risk of the cancer coming back, Al Jazeera and Scientific American reported. The trial involved over 1,100 patients, according to Публикации по подписке.

This news immediately triggered a surge in Moderna's stock price, with shares more than doubling, as noted by CNBC International and elEconomista.es. The excitement spread across the biotech sector, with analysts and investors closely watching for more detailed results.

By August 20, coverage in outlets like Nature and CBS Top Stories confirmed that the vaccine had successfully passed its phase 3 trial. Reports also highlighted that similar mRNA-based therapies are now being explored for other cancers, including lung, bladder, and kidney cancer.

Doctors and scientists praised the results as a landmark moment for cancer treatment. However, some analysts, as reported by MarketWatch, cautioned that while the findings are promising, it remains to be seen how broadly the vaccine will be used and how accessible it will be for patients.

As of late August 2026, Moderna and Merck's personalized mRNA cancer vaccine has completed a successful phase 3 trial in high-risk melanoma patients. The data suggest the vaccine can reduce the risk of melanoma returning or spreading after surgery, especially when combined with Keytruda.

The companies are now preparing for the next steps toward regulatory approval. Meanwhile, the results have sparked interest in developing similar vaccines for other types of cancer, with early research already underway in the US and abroad.

Analysts and doctors are waiting for the full trial data to be published, which will provide a clearer picture of the vaccine's effectiveness and safety. Regulatory agencies will review the findings before deciding whether to approve the therapy for wider use.

Other biotech companies are also entering the field, and researchers are closely watching whether mRNA-based cancer vaccines could become a standard part of cancer treatment in the coming years.